Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
Top Cited Papers
- 1 May 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 361 (9369), 1597-1602
- https://doi.org/10.1016/s0140-6736(03)13309-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemiaBlood, 2002
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002
- Oral iron chelation therapy for thalassaemia: an uncertain scene. AnnotationBritish Journal of Haematology, 2000
- Safety profile of the oral iron chelator deferiprone: a multicentre studyBritish Journal of Haematology, 2000
- Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical SettingActa Haematologica, 2000
- Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia MajorNew England Journal of Medicine, 1998
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overloadBritish Journal of Haematology, 1995
- The Development of Hydroxypyridin‐4‐ones as Orally Active Iron ChelatorsAnnals of the New York Academy of Sciences, 1990
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985